Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 8 of 8 for “"Intratumoural heterogeneity"”.

  1. Investigating intratumoural heterogeneity and plasticity with multiplexed single-cell assays

    … resistance given the vast genomic and phenotypic heterogeneity in tumours. There is a recent appreciation of the inherent transcriptomic heterogeneity and plastic nature of cancer cells through single-cell RNA-sequencing (scRNA-seq) of patient tumours. Drug combinations are a promising strategy to …

    cambridge Repository record for Investigating intratumoural heterogeneity and plasticity with multiplexed single-cell assays (opens in a new tab)

  2. Polyclonal interactions in intestinal tumorigenesis

    … sequencing efforts have uncovered significant intratumoural genetic heterogeneity which is inconsistent with such a linear model of tumour progression. Alternative models of tumour evolution have been put forward but they all assume an initial clonal expansion originating from a single …

    cambridge Repository record for Polyclonal interactions in intestinal tumorigenesis (opens in a new tab)

  3. Latent feature models and non-invasive clonal reconstruction

    Intratumoural heterogeneity complicates the molecular interpretation of biopsies, as multiple distinct tumour genomes are sampled and analysed at once. Ignoring the presence of these populations can lead to erroneous conclusions, and so a correct analysis must account for the clonal structure of …

    cambridge Repository record for Latent feature models and non-invasive clonal reconstruction (opens in a new tab)

  4. Genetic Subclones Identify Phenotypic Variation in Diffuse Large B-Cell Lymphoma

    … DLBCL subtypes that account for some of the heterogeneity in clinical outcome following standard therapy. However, not much is known regarding intratumoural heterogeneity. Case studies show that subclones can emerge after targeted therapy and have different drug responses. Thus, our question …

    cambridge Repository record for Genetic Subclones Identify Phenotypic Variation in Diffuse Large B-Cell Lymphoma (opens in a new tab)

  5. Decoding the regulatory role and epiclonal dynamics of DNA methylation in 1482 breast tumours

    … breast cancer is conducted. Both, the level of intratumoural heterogeneity, and the extent of epiallelic burden were found to be prognostic, and revealed an extraordinary distinction in the role of epiclonal dynamics in different breast cancer subtypes. Collectively, the results presented in …

    cambridge Repository record for Decoding the regulatory role and epiclonal dynamics of DNA methylation in 1482 breast tumours (opens in a new tab)

  6. From Mechanisms of Leukaemogenic Dysregulation to New Candidate Therapeutics

    … progenitor cells (HSPCs) that display distinct heterogeneity when profiled at the single-cell level which could explain inconsistencies across previously reported models. Conversely, our model, referred to as ME-Transformed cells, implements a conditionally blocked multipotent haematopoietic …

    cambridge Repository record for From Mechanisms of Leukaemogenic Dysregulation to New Candidate Therapeutics (opens in a new tab)

  7. Multi-modal molecular imaging of radiation therapy response in the tumour vascular microenvironment

    … targeting of solid lesions, yet substantial intratumoural heterogeneity means that treatment planning and monitoring remains a clinical challenge as changes in tumour size can take weeks to manifest and may be misleading. Photoacoustic imaging is an emerging modality for molecular imaging of …

    cambridge Repository record for Multi-modal molecular imaging of radiation therapy response in the tumour vascular microenvironment (opens in a new tab)

  8. EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial

    EGFR TKIs are standard therapy for advanced NSCLC. In order to define their role in early disease, we implemented a phase II trial of neoadjuvant gefitinib in clinical stage I NSCLC. Tumour shrinkage was seen in 43% of patients, with 11% achieving RECIST partial response (PR). Analysis of molecular …

    toronto-retro Repository record for EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial (opens in a new tab)